Abstract A recent phase I/II clinical trial drew serious attention to the therapeutic potential of autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis. However, questions were raised as to whether these beneficial effects should be attributed to the newly reconstituted immune system per se, or to the lymphoablative conditioning regimeninduced immunosuppression, given that T-cell depleting combinational drug therapies were used in the study. We discuss here the possibility that both AHSCT and T-cell depleting therapies may re-program alternatively the immune system, and why transplantation of CD34 + hematopoietic stem cells may offer AHSCT a possible advantage regarding longterm remission.
Introduction
Autologous hematopoietic stem cell transplantation (AHSCT) recently emerged as a promising alternative approach to treat patients suffering from multiple sclerosis (MS) refractory to classical immunomodulatory and immunosuppressive basedtherapies. Its application to treat MS stems from the premise that a dysregulated, autoreactive immune system could be eradicated and replaced by a new, tolerant one. To date, it has been applied not only for the treatment of MS, but also for other autoimmune diseases including type 1 diabetes, systemic lupus erythematosus (SLE) and systemic sclerosis [1] [2] [3] [4] . With respect to MS, patients suffering from inflammation-associated relapsing-remitting MS and treated relatively early in the course of the disease respond better to AHSCT compared to those with long disease duration or those diagnosed with progressive MS. Although potentially hazardous, AHSCT safety has dramatically improved through the years, as the use of lymphoablative regimens has become increasingly prevalent at the expense of myeloablative strategies. Compared to myeloablation, lymphoablation presumably eliminates more selectively lymphocytes and lymphoid progenitors, and therefore minimizes irreversible toxicity to the hematopoietic cellular environment of the bone marrow. As such, it appears to allow for faster recovery and decreases the probability of hematologic and innate immunity complications [5] [6] [7] .
Although the efficiency of AHSCT in MS is increasingly being validated [8] , the immune mechanisms that account for its therapeutic effects are still largely unknown (see Table 1 ). Two basic hypotheses have been proposed to explain the beneficial effects of AHSCT. First, AHSCT may "reset" the immune system, yielding a novel, tolerant immune system. Tolerance could be achieved through 3 nonmutually exclusive mechanisms [9] : 1) elimination of the pre-AHSCT pathogenic T-cell lineage(s) [10] ; 2) shifting of the pre-AHSCT autoreactive T-cell clones toward a tolerant phenotype [11] , and 3) restoration of autoimmune inhibitory immunoregulatory effectors [12] . Yet, an alternative interpretation of the AHSCT data suggests that its clinical benefits might be attributed to the ability of the conditioning regimen to severely deplete Tcell populations for an extended time, thus inducing a state of long-lasting immunosuppression (see Table 2 ). This could be particularly true for AHSCT therapies that use an antibody-mediated lymphoablative conditioning regimen. The validity of either hypothesis is currently a matter of debate in the field of MS and autoimmune diseases [13] .
Based on human clinical studies, the purpose of the present discussion is twofold. First, we argue that a third hypothesis (i.e., namely that both therapies alternatively reprogram the immune system) also needs to be considered. Second, we discuss how transplantation of CD34 + hematopoietic stem cells (HSC) may be advantageous and critical to the establishment of a nonpathological immune system. It needs to be acknowledged that there are relatively scarce studies being conducted to investigate how the immune system specifically changes following AHSCT, largely because the application of AHSCT to treat MS is still in its beginnings. However, because MS is an autoimmune disease, it presents characteristics that often closely parallel those of other autoimmune diseases. Therefore, to substantiate the points made in this review, data generated in the AHSCT clinical trials in the context of other autoimmune diseases will be considered when appropriate. In addition, reviews have been written that focus more specifically on the clinical efficiency aspect of AHSCT in MS (for more detail, see Mancardi and Saccardi's [14] article from 2008 and Capello and colleagues' [15] from 2009). -T cells in combination with preliminary data demonstrating an increase in T-cell receptor excision circles indicated a thymic ontogeny as opposed to an expansion in the peripheral T-cell compartment. Considering that thymic output diminishes as an individual ages [17] , these data suggest a recovery of thymic functions in mature patients, leading to a rejuvenation of the CD4 + T-cell population. Spectratyping analysis of the hypervariable complementarydetermining region 3 (CDR3) encoded within the β chain of T cell receptor (TCR) revealed a widened repertoire diversity within CD4
+ T cells at the two-year follow-up compared to pretreatment. Sequencing analysis of the complementary determining region 3 at the single T-cell clone level estimated that for a majority of clones, 90% of the complementary determining region 3 analyzed were derived posttransplantation. CD8 + T cells also displayed a wider TCR repertoire following AHSCT. Therefore, it appears that through exhaustive clonal renewal, vast TCR rearrangements occur after AHSCT, leading to an augmentation of the T-cell repertoire and clonal diversity.
Similar observations on naive and central memory T cells, recent thymic emigrants, and TCR repertoire following AHSCT with SLE patients have also been reported by Alexander et al. [18] . Thus, not only do they corroborate the conclusions of Muraro et al. [16] , but they also suggest that AHSCT has properties that are disease independent. Note, however, that an early AHSCT investigation did not report the same pre-vs post-AHSCT immune differences. Indeed, in 2004, Sun et al. [19] concluded that the structural and functional phenotypes of reconstituted T cells post-AHSCT were similar to those of pre-transplantation T cells. However, these data were obtained at a 1-year follow-up, whereas the effects in the Muraro et al. [16] and Alexander et al. [18] studies were observed for a span of 2 years following transplantation. Considering that CD34 + hematopoietic stem cell (HSC) grafts are not instantaneous, and that important expansion of the peripheral T-cell compartment takes place during the first 6 months following AHSCT [16] , a 1-year follow-up period may have been insufficient for assessing an immune system reconfiguration that has yet to reach its equilibrium. Finally, no data regarding the functional phenotype of a rejuvenated immune system were reported by Muraro et al. [16] . Such data would be valuable, as defects in immunomodulatory mechanisms are potential etiological components of MS.
In 2009, Zhang et al. [9] reported evidence that AHSCT introduces or reintroduces immunoregulatory mechanisms. Although this study was performed with SLE patients, parallels with MS may possibly be drawn, given that both are autoimmune diseases. Patients underwent lymphoablative AHSCT and immune assays were performed on average 33 months after transplantation. Interestingly, immune phenotypes of transplanted patients were compared to those of healthy individuals and those of SLE patients treated with conventional therapies.
Zhang et al. [9] first compared the pre-and post-AHSCT responsiveness of peripheral blood mononuclear cells (PBMC) to SLE-related nucleosomal histone epitopes in vitro. In patients with lupus, such stimulation induces a strong interferon (IFN)-γ synthesis in CD4 + T cells. After AHSCT, however, IFN-γ production by CD4 + T cells is completely abrogated. It is noteworthy that CD4 + T cells of patients in clinical remission and treated with conventional approaches still exhibit a propensity for IFN-γ production under similar conditions [20] . In contrast, a significant upregulation of interleukin (IL)-13 synthesis occurred with post-AHSCT CD4 + T cells. Interestingly, CD4 + T cells from healthy individuals did not display this production of IL-13, raising the possibility that clinical remission may not necessarily imply that typical physiological parameters are restored. In total, these data suggest that AHSCT in the context of SLE shifts the adaptive immune response to relevant antigens from a Th1/inflammatory toward a Th2/ anti-inflammatory phenotype.
Extrinsic factors, as opposed to intrinsic ones (e.g. CD4 + Tcell sensitivity/responsiveness to the immunogens) mediated these phenotypic changes of CD4 + behavior. Indeed, removing CD8 + T cells from post-AHSCT PBMC restored the production of IFN-γ in CD4 + T cells. In contrast, when post-AHSCT PBMC were stimulated with nucleosomal epitopes in co-culture with CD8 + T cells preserved from the pre-AHSCT stage, IFN-γ production remained elevated. Hence, AHSCT appears to reconfigure CD8 + T cells toward an immunosuppressive phenotype.
The ability of CD8 + T cells to regulate CD4 + T-cell proliferation in vitro also changed remarkably following AHSCT. Indeed, in the presence of irradiated allogenic antigen-presenting cells, both pre-and post-AHSCT CD4 + T cells proliferated roughly 30% more when co-cultured with pre-AHSCT CD8 + T cells compared to control conditions. However, co-culture with post-AHSCT CD8 + cells inhibited the proliferation of either population of CD4 + T cells by 25%. Interestingly, CD8 + T cells from patients treated with conventional therapy neither potentiated nor suppressed CD4 + proliferation. Finally, whereas proliferation potentiation by pre-AHSCT CD8 + T cells was mediated through a cell contact dependent mechanism, transforming growth factor (TGF)-β and IL-10 produced by post-AHSCT CD8 + T cells suppressed CD4 + T-cell proliferation. The elevated levels of FoxP3 detected in CD8 + T cells following AHSCT, along with the ability of post-AHSCT CD8 + T cells to produce TGF-β and suppress CD4 + T-cell proliferation and pro-inflammatory activity suggest that a CD8 TGF-β Treg subset exists within the CD8 + T-cell collective population. Therefore, these CD8 TGF-β Treg cells through immunomodulatory mechanisms could be critical to clinical remission in SLE following AHSCT. Whether they are relevant to the remission that follows AHSCT in MS is still unknown, but the possibility is interesting in light of a recent report implicating CD8
+ T cells in MS [21] .
AHSCT Mechanism of Action: The Immunosuppression Hypothesis
The observations that immune changes accompany clinical remission following AHSCT are correlative. In addition, evidence corroborates the significant and long-lasting immunosuppressive properties of alemtuzumab or rabbit anti-thymocyte globulin (rATG) that have been predominately used to achieve lymphoablation in AHSCT. Hence, alemtuzumab or rATG may dampen the immune system activity, thus inhibiting its capacity to mount autoreactive responses. Because the alemtuzumab-based therapies are efficient with MS, it adds further support to this hypothesis [22] . Note that because the clinical efficacy of rATG has yet to be demonstrated for MS, this discussion will limit itself to alemtuzumab.
Alemtuzumab, also known as Campath-1H, targets CD52, a glycoprotein present at the surface of most immune cells, including T-lymphocytes [23] [24] [25] . One early report suggested that it is present on more than 95% of thymocytes [26] . Importantly, however, its expression on CD34 + HSCs is low [27] . Binding of alemtuzumab to CD52 leads to cytotoxicity through different mechanisms, including antibody-mediated cytolysis [28] , complement-induced membrane attack complex [29] , and apoptosis [30, 31] . The cytolytic effects of alemtuzumab lead to prolonged lymphopenia and a complete reconstitution of T-lymphocyte populations may take as long as 5 years [32] .
Characterization of the immune profile in the year following alemtuzumab therapy in MS patients indicated that reconstitution of the different populations of lymphocytes does not evolve at the same rate, and that overall reconstitution proceeds in 2 phases [23] . The early phase occurs during the first 6 months. Initially, trace amounts of CD4 + and CD8 high Tregs largely contribute to this effect; the representation of these cells at 3 and 6 months after alemtuzumab doubled and tripled, respectively, compared to pretreatment levels. In addition, the CD8 + T-cell population recovers faster than CD4 + T cells in the early phase. Finally, during the late phase T cells ratios among the different T-cell populations re-equilibrated toward pretreatment levels. Note, however, that absolute cell counts are still decreased 1 year after treatment, with the total CD4 + and CD8 + T-cell populations reaching only 32% and 55% of the pretreatment levels, respectively.
Changes in T-cell properties are also seen at the individual cell level after alemtuzumab administration [33] . In vitro Tcell proliferative potential is substantially increased 3 months after therapy compared to pretreatment. This occurs both in response to either unstimulated or myelin basic protein exposure conditions. Furthermore, T cells are also more susceptible to passive and Fas-mediated apoptosis.
Recent evidence suggests that a subset of B cells has an active role in the etiology of MS and may potentiate activity of MS-promoting T cells [34] . Reports that administration of antibody Rituximab, which targets CD20 on B cells, is effective at treating MS corroborate this hypothesis [34, 35] . Interestingly, alemtuzumab also substantially affects B-cell homeostasis, and the reconstitution of these cells contrasts dramatically with that of the T cells [36] . Indeed, by month 3 after an alemtuzumab pulse, B cells have not only reestablished their pretreatment levels, but continue to proliferate massively and reach 165% of their original pretreatment levels at the 1-year follow-up. This reconstitution is essentially mediated by the generation of immature B cells, as opposed to proliferation of memory B cells.
AHSCT Mechanism of Action: Reconciling Hypothesis
Nonmyeloablative conditioning regimens followed by AHSCT, alemtuzumab-based therapies and possibly rATGbased therapies all have the potential to significantly improve the prognosis of MS patients. As such, it can be expected that clinical experiments with these therapies in the near future will become less aimed at demonstrating their clinical potential per se, and more focused on 1) the investigation of their therapeutic mechanisms, 2) which category of patients benefits the most from them, and 3) how to minimize side effects. Concerning the molecular and cellular mechanisms involved in the benefit resulting from these therapies, whether the theoretical gap existing between nonmyeloablation followed by AHSCT on the one hand, and the alemtuzumab-based therapies on the other, will remain is unclear. Indeed, as both therapies involve lymphoablation, substantial overlap in their physiological effects may exist. The therapeutic effects provided by each approach may arise from a common mechanism, and therefore reconciling hypotheses should be considered. One such hypothesis is that in response to the lymphoablative nature of either therapies, the reconstitution and adaptation of the immune system to the lymphoablative drugs re-programs this system de facto, which then becomes either incapable of mounting MS autoimmune attacks of clinical importance, or self-tolerant.
The extent to which AHSCT leads to an immune reset or reconfiguration is not clear. No consensual operational definition of what "immune reset" exactly represents has been proposed. Hence, the lack of such definition can make the use of the term "reset" misleading, as it entails a return to a default state of immune parameters. In reality, this may not necessarily be the case, and demonstrating that the immune system of an MS patient returns to a prepathological state is technically challenging. Furthermore, and as previously mentioned, there are differences in the phenotype of a post-AHSCT immune system and that of a healthy individual [9] . One possible explanation for this is that the ontology of the post-AHSCT immune system is influenced by internal and external factors that are likely to be markedly different from those typically operating in early life. Indeed, the physiological parameters of an MS patient (e.g., immune cell ratios, metabolism, and so forth) are different from those of the fetal and infancy stages, and the exposure to environmental factors (e.g., pathogenic agents) that can impact immune development are also different [37] . Of note, persisting T cells also have been detected in patients following either myeloablative or nonmyeloablative conditioning regimen, and these may also influence the development of the reconstituting immune system [38, 39] . Thus, it is not clear at this point whether the immune system is actually "reset" in the true sense of the term. However, the characteristics that the immune system acquires following AHSCT certainly suggest that it has become alternatively programmed.
On the other hand, alemtuzumab does have important effects as previously mentioned on the ratios of different Tcell populations [23] . Thus, the benefits alemtuzumab provides to MS patients may be a consequence of these ratio shifts and not necessarily because T-cell subpopulations to which MS effectors belong are significantly decreased in absolute numbers. Indeed, it is still unknown whether alemtuzumab is effective because the pool of autoreactive T cells is greatly diminished, or because autoreactive mechanisms are altered by immunoregulatory mechanisms, for example provided by CD4 + /CD25 + Tregs which recover relatively fast in number. Note also that a combination of both hypotheses is possible. In 2009, Jones and Coles [40] similarly proposed that alterations in the overall immune status and not lymphopenia per se were probably critical for the beneficial effects of alemtuzumab in MS.
The immune system of patients in either therapy likely presents similar characteristics in the aftermath of the lymphoablative conditioning regimen or the alemtuzumab pulse cycle. However, divergences emerge with the transplantation of a graft of HSC, which is free of T-cell clones [41] . For instance, cell numbers appeared to recover more rapidly in the Muraro et al. [16] study in 2005 than in the Cole et al. [22] study in 2008. There also appears to be a higher proportion of patients achieving progression-free survival with AHSCT at a 3-year follow-up, although these are still preliminary results [8, 22] . Yet, this lays the ground for a fundamental question: How does transplantation of CD34 + HSCs following a lymphoablative conditioning regimen alter the reconstitution and reprogramming of the immune system?
It is plausible that alemtuzumab modulates lymphoid progenitor niches within the thymus by eliminating lymphoid progenitors from existing niches or by creating novel niches to meet the demands for important proliferation to ensure a prompt return for T-cell homeostasis. Note that these possibilities are not mutually exclusive. These niches will replenish in time through the proliferative activity of residual lymphoid progenitors (blood CD34 + HSCs), and possibly through dedifferentiation of B cells to uncommitted lymphoid progenitors. The contribution of B cells might be relevant in a context of T-cell lymphopenia, considering the major burst of proliferative activity that they exhibit following depletion and their capacity to dedifferentiate into T-cell progenitors [42] . Among those cellular types, it can be argued that CD34 + HSCs have the highest potential for the reconstitution of a homeostatic, nonautoreactive immune system. Indeed, alemtuzumab-surviving lymphoid progenitors may still possess the capacity to generate MS promoting T-lymphocytes, whereas the ontological and cellular history of B cells could have set epigenetic barriers that incapacitate them from generating a homeostatic immune system. Thus, without transplantation, the competitive advantage possessed by endogenous CD34 + HSCs over the other cellular populations for vacant lymphoid progenitor niches is relatively small as compared to that obtained after transplantation. This may be a key component of the mechanism responsible for the different, although still preliminary, clinical outcomes between AHSCT and alemtuzumab-pulse therapies.
Conclusion
Despite technical challenges associated with comparing a pre-vs post-AHSCT immune system, the data gathered thus far from varied clinical trials yield converging evidence that AHSCT fundamentally modifies the immune system in ways that are hardly possible with lymphoablation per se. This conclusion, along with the increasing expertise that is being developed around the world with AHSCT therapies allows for a cautious optimism for the use of AHSCT in the treatment of MS.
